Tier 3 — preclinical

The therapeutic potential of resveratrol: a review of clinical trials

Berman AY, Motechin RA, Wiesenfeld MY, Holz MK
NPJ Precision Oncology 2017 1:35

Bibliography

PubMed
PMID 28989978
PubMed Central
PMC5630227
DOI
10.1038/s41698-017-0038-6
Funding
Not stated as industry-sponsored in the abstract; academic review (Yeshiva University / Albert Einstein College of Medicine).
Competing interests
Not stated as a specific conflict in the abstract.

Study snapshot

DesignNarrative review of published clinical trials
ModelNot applicable — literature review
SampleNot applicable
InterventionNot applicable
DurationNot applicable
Endpoints

What the study showed, in plain terms

This review looked across resveratrol's human clinical trials for cancer, neurological disorders, heart disease, diabetes, fatty liver disease, and obesity. It found resveratrol was generally well tolerated and improved some disease markers in neurological, cardiovascular, and diabetes trials, but had inconsistent or even unfavourable effects in some cancer and fatty-liver trials — with poor bioavailability a recurring problem throughout.

Key findings

Across the reviewed clinical trials, resveratrol was well tolerated and beneficially influenced disease biomarkers in neurological disorders, cardiovascular disease, and diabetes trials. However, effects in certain cancers and in non-alcoholic fatty liver disease were ambiguous or sometimes unfavourable. Poor bioavailability was identified as the major recurring obstacle across the clinical trial literature.

What this study can and cannot tell us

A narrative review, not a systematic review or meta-analysis with a defined search strategy or quality scoring — its summary judgements about which disease areas show benefit should be treated as a starting point, not a substitute for reading the individual trials.

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability